GR3002022T3 - 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors - Google Patents

3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors

Info

Publication number
GR3002022T3
GR3002022T3 GR90400772T GR900400772T GR3002022T3 GR 3002022 T3 GR3002022 T3 GR 3002022T3 GR 90400772 T GR90400772 T GR 90400772T GR 900400772 T GR900400772 T GR 900400772T GR 3002022 T3 GR3002022 T3 GR 3002022T3
Authority
GR
Greece
Prior art keywords
dihydroisoxazoles
disubstituted
transglutaminase inhibitors
transglutaminase
inhibitors
Prior art date
Application number
GR90400772T
Other languages
English (en)
Inventor
Arlindo L Castelhano
Alexander Krantz
Diana H Pliura
Michael C Venuti
Young Lawrence M De
Original Assignee
Syntex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex Inc filed Critical Syntex Inc
Publication of GR3002022T3 publication Critical patent/GR3002022T3/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
GR90400772T 1986-03-14 1991-05-30 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors GR3002022T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83974386A 1986-03-14 1986-03-14

Publications (1)

Publication Number Publication Date
GR3002022T3 true GR3002022T3 (en) 1992-12-30

Family

ID=25280527

Family Applications (1)

Application Number Title Priority Date Filing Date
GR90400772T GR3002022T3 (en) 1986-03-14 1991-05-30 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors

Country Status (13)

Country Link
EP (1) EP0237082B1 (el)
JP (1) JPS62252779A (el)
KR (1) KR900006545B1 (el)
AT (1) ATE63906T1 (el)
AU (1) AU599636B2 (el)
DE (1) DE3770294D1 (el)
DK (1) DK130387A (el)
ES (1) ES2038609T3 (el)
GR (1) GR3002022T3 (el)
HU (2) HU199809B (el)
IL (1) IL81887A0 (el)
NZ (1) NZ219607A (el)
ZA (1) ZA871860B (el)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2738486B2 (ja) * 1992-11-20 1998-04-08 ファイザー製薬株式会社 抗炎症剤としての新規なイソオキサゾリン類
CA2173875A1 (en) * 1993-11-01 1995-05-11 Hideyuki Saika Endothelin receptor antagonists
US5710159A (en) * 1996-05-09 1998-01-20 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
KR19990067184A (ko) 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
US6586466B2 (en) 1995-10-30 2003-07-01 Smithkline Beecham Corporation Carbohydrazide-protease inhibitors
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
TWI245035B (en) 1998-06-26 2005-12-11 Ono Pharmaceutical Co Amino acid derivatives and a pharmaceutical composition comprising the derivatives
EP1097929A4 (en) 1998-07-14 2005-12-21 Ono Pharmaceutical Co AMINO ACID DERIVATIVES AND MEDICAMENTS IN WHICH THESE DERIVATIVES ARE THE ACTIVE INGREDIENTS
US20030144175A1 (en) 1998-12-23 2003-07-31 Smithkline Beecham Corporation Protease inhibitors
WO2001034599A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
WO2001034600A1 (en) 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
AU2001243441B2 (en) 2000-03-21 2004-11-25 Smithkline Beecham Corporation Protease inhibitors
US8143210B2 (en) 2002-02-14 2012-03-27 The Board Of Trustees Of The Leland Stanford Junior University Enzyme treatment of foodstuffs for celiac sprue
ATE505201T1 (de) 2002-02-14 2011-04-15 Univ Leland Stanford Junior Enzymbehandlung von nahrungsmitteln für zöliakie- sprue
US6902781B2 (en) 2002-04-08 2005-06-07 Konica Corporation Ink-jet recording medium, silica particles and silica dispersion
CA2487247A1 (en) 2002-05-14 2003-11-27 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for celiac sprue
US7265093B2 (en) * 2002-05-14 2007-09-04 The Board Of Trustees Of The Leland Stanford Junior University Drug therapy for Celiac Sprue
EP1563300B1 (en) 2002-11-20 2012-04-18 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic method for celiac sprue
US7579313B2 (en) 2003-11-18 2009-08-25 The Board Of Trustees Of The Leland Stanford Junior University Transglutaminase inhibitors and methods of use thereof
US7628985B2 (en) 2004-04-26 2009-12-08 The Board Of Regents Of The Leland Stanford Junior University Therapeutic enzyme formulations and uses thereof in celiac sprue and/or dermatitis herpetoformis
GB0515003D0 (en) 2005-07-21 2005-08-31 Univ Aston Medical devices and coatings therefor
WO2008115411A1 (en) 2007-03-16 2008-09-25 The Board Of Trustees Of The Leland Stanford Junior University Combination enzyme therapy for digestion of dietary gluten
MX2009012847A (es) * 2007-06-13 2009-12-08 Bristol Myers Squibb Co Analogos dipeptidicos como inhibidores de factores de coagulacion.
WO2009067799A1 (en) * 2007-11-27 2009-06-04 The University Of Manitoba Use of transglutaminase inhibitor in skin treatment
US8927551B2 (en) 2009-05-18 2015-01-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US8765735B2 (en) 2009-05-18 2014-07-01 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase
US9149465B2 (en) 2009-05-18 2015-10-06 Infinity Pharmaceuticals, Inc. Isoxazolines as inhibitors of fatty acid amide hydrolase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283403A (en) * 1976-06-14 1981-08-11 Eli Lilly And Company Substituted isoxazolines for control of plant phytopathogens
WO1981001145A1 (en) * 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4481190A (en) 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists

Also Published As

Publication number Publication date
HU199809B (en) 1990-03-28
EP0237082B1 (en) 1991-05-29
KR870008863A (ko) 1987-10-21
IL81887A0 (en) 1987-10-20
JPS62252779A (ja) 1987-11-04
DK130387A (da) 1987-09-15
NZ219607A (en) 1990-11-27
ZA871860B (en) 1988-10-26
EP0237082A2 (en) 1987-09-16
DK130387D0 (da) 1987-03-13
ES2038609T3 (es) 1993-08-01
EP0237082A3 (en) 1988-09-14
KR900006545B1 (ko) 1990-09-13
ATE63906T1 (de) 1991-06-15
AU599636B2 (en) 1990-07-26
HUT44244A (en) 1988-02-29
DE3770294D1 (de) 1991-07-04
HU201032B (en) 1990-09-28
AU6998787A (en) 1987-09-17

Similar Documents

Publication Publication Date Title
GR3002022T3 (en) 3,5-disubstituted 4,5-dihydroisoxazoles as transglutaminase inhibitors
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
DE69719408T2 (de) Verwendung von Strontiumsälze zur Behandlung von Arthrose
DE3780618T2 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
SG48298A1 (en) Saccharin deriatives useful as proteolytic enzymeinhibitors and preparation of
PH18029A (en) Tetrahydronaphthalene and indane derivatives
ZA867530B (en) Composition for the treatment of acne
AU2949889A (en) Reverse transcriptase inhibitors for treating adenocarcinomas
AU587144B2 (en) Use of medetomidine compounds for treatment of anxiety disorders
AU6142186A (en) Use of melatonin or related compounds for the treatment of psoriasis
IN167848B (el)
PH24568A (en) Use of bezafibrate for treating diabetes
DE3856329D1 (de) Verwendung von Ethisterone zur topischen Behandlung von Akne oder androgenetischer Alopezie
FI903010A0 (fi) Merkaptoacylaminosyrablod- trycksmediciner.
GR3017358T3 (en) 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants.
DE3462688D1 (en) 1,7-diphenyl-3-methylaza-7-cyano-8-methylnonane useful in combating diseases
IT8521950A0 (it) Procedimenti per trattare pellami ed apparecchiatura per attuare il procedimento.
IT1192097B (it) Dispositivo per l'introduzione delle pelli in macchine per conceria
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
AU5199286A (en) New use of 1,4-dihydropyridine derivatives
DE3478745D1 (en) 6h-dibenz (b,e)(1,4)oxathiepin compounds
ATE226062T1 (de) Verwendung von co2 zur kosmetischen behandlung von segmentären lipodystrophien
SU1208623A1 (ru) Препарат для лечения копытной гнили "формакаст"
PHUM6382Z (en) Composition for the treatment of pimples
IT1228444B (it) Apparecchiatura per l'essiccazione di pelli o simili.